NeuroSense has reported positive preliminary results from a biomarker study investigating a combination platform therapy for treatment of Parkinson’s Disease (PD).
In the study which compared blood samples from 30 patients with PD to 30 healthy individuals, AGO2 (Argonaute 2) was reduced by a statistically significant level. AGO2 is important in the regulation of alpha-synuclein accumulation in the brain and dysregulation can lead to motor control impairment. The change was not observed in late-stage PD patients – with the company saying that the trend could be related to disease onset.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe results from the study complement a Phase IIa clinical trial conducted in people living with amyotrophic lateral sclerosis (ALS). Neurosense’s platform combination therapy induced a significant increase in AGO2. LC3, a protein that is implicated in neurodegenerative disorders including PD, was also increased.
“We believe these results strengthen the scientific rationale to develop NeuroSense’s platform technology for PD, as the mechanism of action may be helpful in targeting disease-specific pathways, specifically AGO2 dysregulation,” said Dr. Shiran Zimri, NeuroSense’s VP of R&D.
“We believe that these data denote the potential of NeuroSense’s platform technology to target early stages of Parkinson’s disease. This is particularly relevant as early detection of PD is becoming more common,” added NeuroSense CEO, Alon Ben-Noon.
